Citadel Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57.1M Buy
910,400
+310,400
+52% +$24.8M 0.01% 1241
2025
Q4
$57.2M Buy
600,000
+96,700
+19% +$9.48M 0.01% 1293
2025
Q3
$49.1M Buy
503,300
+33,300
+7% +$3.45M 0.01% 1391
2025
Q2
$50.5M Buy
470,000
+57,200
+14% +$5.79M 0.01% 1240
2025
Q1
$41.6M Buy
412,800
+37,700
+10% +$3.8M 0.01% 1294
2024
Q4
$33.5M Buy
375,100
+88,100
+31% +$7.76M 0.01% 1636
2024
Q3
$24.1M Sell
287,000
-21,800
-7% -$1.72M ﹤0.01% 1858
2024
Q2
$23.8M Buy
308,800
+113,100
+58% +$8.28M ﹤0.01% 1823
2024
Q1
$13.4M Sell
195,700
-475,800
-71% -$30.6M ﹤0.01% 2546
2023
Q4
$38.8M Sell
671,500
-280,200
-29% -$15M 0.01% 1380
2023
Q3
$50.2M Buy
951,700
+579,700
+156% +$30.4M 0.01% 1073
2023
Q2
$20.1M Sell
372,000
-180,000
-33% -$9.4M ﹤0.01% 1880
2023
Q1
$27.6M Buy
552,000
+390,000
+241% +$18.4M 0.01% 1608
2022
Q4
$7.5M Sell
162,000
-290,200
-64% -$12.6M ﹤0.01% 3226
2022
Q3
$17.5M Sell
452,200
-588,800
-57% -$23.6M ﹤0.01% 2023
2022
Q2
$38.8M Buy
1,041,000
+291,300
+39% +$11.9M 0.01% 1218
2022
Q1
$33.2M Buy
749,700
+5,900
+0.8% +$256K 0.01% 1449
2021
Q4
$31.6M Sell
743,800
-612,500
-45% -$25.7M 0.01% 1552
2021
Q3
$58.9M Sell
1,356,300
-38,400
-3% -$1.7M 0.01% 1001
2021
Q2
$59.6M Buy
1,394,700
+168,500
+14% +$7.09M 0.01% 992
2021
Q1
$47.4M Buy
1,226,200
+663,200
+118% +$25.1M 0.01% 1088
2020
Q4
$20.2M Sell
563,000
-265,600
-32% -$9.57M 0.01% 1787
2020
Q3
$31.7M Buy
828,600
+218,400
+36% +$8.42M 0.01% 1172
2020
Q2
$21.4M Buy
610,200
+321,000
+111% +$11.6M 0.01% 1448
2020
Q1
$9.44M Buy
289,200
+94,800
+49% +$3.7M ﹤0.01% 1916
2019
Q4
$8.79M Sell
194,400
-194,400
-50% -$8.13M ﹤0.01% 2340
2019
Q3
$15.8M Sell
388,800
-79,800
-17% -$3.38M 0.01% 1705
2019
Q2
$20.1M Buy
468,600
+148,100
+46% +$5.7M 0.01% 1422
2019
Q1
$12.3M Buy
320,500
+93,700
+41% +$3.58M 0.01% 1831
2018
Q4
$8.02M Sell
226,800
-107,800
-32% -$3.91M ﹤0.01% 2160
2018
Q3
$12.9M Buy
334,600
+62,200
+23% +$2.17M 0.01% 1824
2018
Q2
$8.91M Buy
272,400
+183,500
+206% +$5.53M ﹤0.01% 2063
2018
Q1
$2.43M Sell
88,900
-181,700
-67% -$4.94M ﹤0.01% 3439
2017
Q4
$6.71M Buy
270,600
+194,800
+257% +$5.37M ﹤0.01% 2141
2017
Q3
$2.21M Sell
75,800
-49,100
-39% -$1.36M ﹤0.01% 3289
2017
Q2
$3.46M Buy
124,900
+72,000
+136% +$1.91M ﹤0.01% 2513
2017
Q1
$1.32M Sell
52,900
-226,200
-81% -$5.5M ﹤0.01% 3596
2016
Q4
$6.04M Buy
279,100
+178,300
+177% +$3.89M 0.01% 1796
2016
Q3
$2.4M Buy
100,800
+22,400
+29% +$534K ﹤0.01% 2755
2016
Q2
$1.83M Buy
78,400
+46,100
+143% +$997K ﹤0.01% 2845
2016
Q1
$608K Sell
32,300
-81,200
-72% -$1.43M ﹤0.01% 4130
2015
Q4
$2.09M Buy
113,500
+28,500
+34% +$511K ﹤0.01% 2688
2015
Q3
$1.4M Buy
85,000
+9,800
+13% +$168K ﹤0.01% 3382
2015
Q2
$1.33M Buy
75,200
+4,600
+7% +$82.2K ﹤0.01% 3592
2015
Q1
$1.25M Sell
70,600
-19,600
-22% -$310K ﹤0.01% 3647
2014
Q4
$1.2M Sell
90,200
-91,400
-50% -$1.17M ﹤0.01% 3540
2014
Q3
$2.15M Buy
181,600
+57,600
+46% +$725K ﹤0.01% 2783
2014
Q2
$1.58M Sell
124,000
-400
-0.3% -$5.2K ﹤0.01% 2967
2014
Q1
$1.68M Sell
124,400
-388,700
-76% -$5.1M ﹤0.01% 2834
2013
Q4
$6.17M Buy
513,100
+370,200
+259% +$4.37M 0.01% 1528
2013
Q3
$1.68M Sell
142,900
-3,200
-2% -$34.6K ﹤0.01% 2575
2013
Q2
$1.35M Buy
+146,100
New +$1.24M ﹤0.01% 2879

Other funds holding BSX

Citadel Advisors's BSX Position: Q1 2026 in Review

Citadel Advisors reduced its Boston Scientific (BSX) stake by 12% in Q1 2026, selling an estimated $44.7M and leaving 4,217,314 shares worth $265M. The position accounts for 0.04% of the portfolio, ranked #342.

Citadel Advisors first reported a position in BSX in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.12B in Q3 2023. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Citadel Advisors held 4,217,314 shares of Boston Scientific worth $265M as of Q1 2026.
  • Citadel Advisors sold 558,304 Boston Scientific shares in Q1 2026, an estimated $44.7M.
  • Boston Scientific made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #342 holding.
  • Citadel Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Boston Scientific position peaked at $1.12B in Q3 2023.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.